ALN-RSV01: Completed Phase II enrollment

Alnylam completed enrollment of 24 patients in a double-blind, placebo-controlled, U.S. and Australian Phase II trial (ALN-RSV01-106) evaluating inhaled ALN-RSV01 given once daily for 3 days. Cubist a...